Hundreds of thousands of people with advanced head and neck cancer could live longer without their cancer returning thanks to ...

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

Shares in both companies were lower after one study met the primary goal and a second missed its main target in their drug ...

Regeneron shares fell nearly 13% before the bell on Friday after its experimental drug for patients with a type of lung ...

A new study found the drug kept head and neck cancers at bay for five years compared to 30 months with standard care ...

Ivonescimab helped cut the risk of lung tumor progression in half in a multi-country Phase 3 trial. But it hasn’t yet clearly ...

An experimental COPD drug from Sanofi and Regeneron showed mixed results in a pair of studies, sending the companies' shares ...

The company is preparing a Phase 3 trial of enobosarm with a novel formulation that could extend its patent life.

Spero Therapeutics and partner GSK are stopping a late-stage trial of an experimental oral drug for complicated urinary tract ...

In the past, most targeted drug development efforts relied on single biomarkers, but cancer is far more complex. BostonGene’s ...

In this video interview, Ron Lanton, partner, Lanton Law, discusses how a potential increase in drug costs could affect the ...

A British man on trial for drug offenses has pleaded for leniency in a court on the Indonesian tourist island of Bali after a ...